Prognostic factors for dogs with mammary inflammatory carcinoma: 43 cases (2003-2008)

Journal of the American Veterinary Medical Association

Volumn 235, Issue 8, 2009, Pages 967-972

  Marconato, Laura ^a,h   Romanelli, Giorgio ^b   Stefanello, Damiano ^c   Giacoboni, Claudio ^d   Bonfanti, Ugo ^e,i   Bettini, Giuliano ^f   Finotello, Riccardo ^a   Verganti, Sara ^a   Valenti, Paola ^a,h   Ciaramella, Luigia ^a   Zini, Eric ^g  

^a Clinica Veterinaria EArca   (Italy)

^b Clinica Veterinaria Nerviano   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Clinica Veterinaria sant'Antonio   (Italy)

^e Clinica Veterinaria Gran Sasso   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF ZURICH   (Switzerland)

^h Animal Oncology and Imaging Center   (Switzerland)

ⁱ NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; CARCINOMA; DOG; DOG DISEASE; EXPERIMENTAL NEOPLASM; FEMALE; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; DOG DISEASES; DOGS; FEMALE; MAMMARY NEOPLASMS, ANIMAL; SURVIVAL RATE;

ANIMALIA; CANIS FAMILIARIS;

EID: 70350524874     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.235.8.967     Document Type: Article

References (22)

1. Singletary SE, Cristofanilli M. Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol 2008;35:7-10. (Pubitemid 351282390)
2. Susaneck SJ, Allen TA, Hoopes J, et al. Inflammatory mammary carcinoma in the dog. J Am Antm Hosp Assoc 1983;9:971-976.
3. Perez Alenza MD, Tabanera E, Pen̄a L. Inflammatory mammary carcinoma in dogs: 33 cases (1995-1999). J Am Vet Med Assoc 2001;219:1110-1114.
4. Amparo RS, Angel CDM, Ana LH, et al. Inflammatory breast carcinoma: pathological or clinical entity? Breast Cancer Res Treat 2000;64:269-273.
5. Peña L, Perez-Alenza MD, Rodriguez-Bertos A, et al. Canine inflammatory mammary carcinoma: histopathology, immunohis-tochemistry and clinical implications of 21 cases. Breast Cancer Res Treat 2003;78:141-148.
6. Lana SE, Rutteman GR, Withrow SJ. Tumors of the mammary gland. In: Withrow SJ, Vail DM, eds. Withrow & MacEwens small animal clinical oncology. 4th ed. Philadelphia: WB Saunders Co, 2007;619-636.
7. Ellis LM, Bland Kl, Copeland EM HI. Inflammatory breast cancer: advances in therapy. Semin Surg Oncol 1988;4:261-267.
8. Dawood S, Ueno NT, Cristofanilli M. The medical treatment of inflammatory breast cancer. Semin Oncol 2008;35:64-71. (Pubitemid 351282392)
9. Queiroga FL, Perez-Alenza MD, Silvan G, et al. Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance. Anticancer Res 2005;25:4269-4275.
10. Veterinary Cooperative Oncology Group. Veterinary Cooperative Oncology Group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats. Vet Comp Oncol 2004;2:194-213.
11. Attia-Sobol I, Ferrière JP, Curé H, et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer 1993;29A:1081-1088.
12. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, et al. Adjuvant post-operative chemotherapy in bitches with mammary cancer. J Vet Med A Physiol Pathol Clin Med 2001;48:85-96.
13. Simon D, Schoenrock D, Baumgartner W, et al. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med 2006;20:1184-1190.
14. Marconato L, Lorenzo RM, Abramo F, et al. Adjuvant gemcitabi-ne after surgical removal of aggressive malignant mammary tumors in dogs. Vet Comp Oncol 2008;6:90-101.
15. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40:321-329.
16. Cristofanilli M, Buzdar AU, Sneige N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 2001;92:1775-1782.
17. Bristol IJ, Buchholz TA. Inflammatory breast cancer: current concepts in local management. Breast Dis 2005-2006;22:75-83.
18. Woodward WA, Buchholz TA. The role of locoregional therapy in inflammatory breast cancer. Semin Oncol 2008;35:78-86.
19. Singletary SE. Surgical management of inflammatory breast cancer. Semin Oncol 2008;35:72-77.
20. Evens AM, Bitran JD. Adjuvant chemotherapy. In: Perry MC, ed. The chemotherapy source book. Philadelphia: Lippincott Williams & Wilkins, 2001;55-70.
21. Vtswanathan K, Dhabhar FS. Stress-induced enhancement of leukocyte trafficking into sites of surgery or immune activation. Proc Natl Acad SciUSA 2005;102:5808-5813.
22. Stockhaus C, Kohn B, Rudolph R, et al. Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma. J Small Anim Pract 1999;40:326-331.